Code No. | Product | Discontinued date | Manufacturer |
---|---|---|---|
A07717 | Anti-CD34 mAb-FITC/Anti-CD33 mAb-PE/Anti-CD45 mAb-ECD | 2019/03/31 | BC |
A07718 | Anti-CD34 mAb-FITC/Anti-CD117 mAb-PE/Anti-CD45 mAb-ECD | 2019/03/31 | BC |
A07719 | Anti-HLA-DR mAb-FITC/Anti-CD34 mAb-PE/Anti-CD45 mAb-ECD | 2019/03/31 | BC |
A07720 | Anti-HLA-DR mAb-FITC/Anti-CD13 mAb-PE/Anti-CD45 mAb-ECD | 2019/03/31 | BC |
A07721 | Anti-CD15 mAb-FITC/Anti-CD33 mAb-PE/Anti-CD45 mAb-ECD | 2019/03/31 | BC |
A07722 | Anti-CD14 mAb-FITC/Anti-CD13 mAb-PE/Anti-CD45 mAb-ECD | 2019/03/31 | BC |
A07723 | Anti-CD41 mAb-FITC/Anti-Glycophorin A mAb-PE/Anti-CD45 mAb-ECD | 2019/03/31 | BC |
A07724 | Anti-HLA-DR mAb-FITC/Anti-CD7 mAb-PE/Anti-CD45 mAb-ECD | 2019/03/31 | BC |
A07725 | Anti-CD5 mAb-FITC/Anti-CD7 mAb-PE/Anti-CD3 mAb-ECD | 2019/03/31 | BC |
A07726 | Anti-CD8 mAb-FITC/Anti-CD4 mAb-PE/Anti-CD3 mAb-ECD | 2019/03/31 | BC |
A07727 | Anti-CD25 mAb-FITC/Anti-CD4 mAb-PE/Anti-CD3 mAb-ECD | 2019/03/31 | BC |
A07728 | Anti-CD16 mAb-FITC/Anti-CD56 mAb-PE/Anti-CD3 mAb-ECD | 2019/03/31 | BC |
A07729 | Neg. Ctrl.-FITC/Neg. Ctrl.-PE/Anti-CD45 mAb-ECD | 2019/03/31 | BC |
A07730 | Neg. Ctrl.-FITC/Neg. Ctrl.-PE/Anti-CD19 mAb-ECD | 2019/03/31 | BC |
A07731 | Neg. Ctrl.-FITC/Neg. Ctrl.-PE/Anti-CD3 mAb-ECD | 2019/03/31 | BC |
A07732 | Neg. Ctrl.-FITC/Neg. Ctrl.-PE/Neg. Ctrl.-ECD | 2019/03/31 | BC |
A07733 | Anti-CD3 mAb-FITC/Anti-CD4 mAb-PE | 2019/03/31 | BC |
A07734 | Anti-CD3 mAB-FITC/Anti-CD8 mAb-PE | 2019/03/31 | BC |
A07735 | Anti-CD3 mAb-FITC/Anti-CD16 mAb+Anti-CD56 mAb-PE | 2019/03/31 | BC |
A07736 | Anti-CD3 mAb-FITC/Anti-CD19 mAb-PE | 2019/03/31 | BC |
A07737 | Anti-CD3 mAb-FITC/Anti-HLA-DR mAb-PE | 2019/03/31 | BC |
A07738 | Anti-CD45 mAb-FITC/Anti-CD14 mAb-PE | 2019/03/31 | BC |
A07739 | Anti-HLA-B27 mAb-FITC/Anti-HLA-B7 mAb-PE | 2019/03/31 | BC |
A07742 | Anti-CD1a (Human) mAb-PE | 2019/03/31 | BC |
A07743 | Anti-CD2 (Human) mAb-FITC | 2019/03/31 | BC |
A07744 | Anti-CD2 (Human) mAb-PE | 2019/03/31 | BC |
A07745 | Anti-CD2 (Human) mAb-PC5 | 2019/03/31 | BC |
A07746 | Anti-CD3 (Human) mAb-FITC | 2019/03/31 | BC |
A07747 | Anti-CD3 (Human) mAb-PE | 2019/03/31 | BC |
A07748 | Anti-CD3 (Human) mAb-ECD | 2019/03/31 | BC |
A07749 | Anti-CD3 (Human) mAb-PC5 | 2019/03/31 | BC |
A07750 | Anti-CD4 (Human) mAb-FITC | 2019/03/31 | BC |
A07751 | Anti-CD4 (Human) mAb-PE | 2019/03/31 | BC |
A07752 | Anti-CD4 (Human) mAb-PC5 | 2019/03/31 | BC |
A07753 | Anti-CD5 (Human) mAb-PE | 2019/03/31 | BC |
A07754 | Anti-CD5 (Human) mAb-PC5 | 2019/03/31 | BC |
A07755 | Anti-CD7 (Human) mAb-FITC | 2019/03/31 | BC |
A07756 | Anti-CD8α (Human) mAb-FITC | 2019/03/31 | BC |
A07757 | Anti-CD8α (Human) mAb-PE | 2019/03/31 | BC |
A07758 | Anti-CD8α (Human) mAb-SPRD | 2019/03/31 | BC |
A07759 | Anti-CD10 (Human) mAb-FITC | 2019/03/31 | BC |
A07760 | Anti-CD10 (Human) mAb-PE | 2019/03/31 | BC |
A07761 | Anti-CD10 (Human) mAb-PC5 | 2019/03/31 | BC |
A07762 | Anti-CD13 (Human) mAb-PE | 2019/03/31 | BC |
A07763 | Anti-CD13 (Human) mAb-PC5 | 2019/03/31 | BC |
A07764 | Anti-CD14 (Human) mAb-PE | 2019/03/31 | BC |
A07765 | Anti-CD14 (Human) mAb-PC5 | 2019/03/31 | BC |
A07766 | Anti-CD16 (Human) mAb-PE | 2019/03/31 | BC |
A07767 | Anti-CD16 (Human) mAb-PC5 | 2019/03/31 | BC |
A07768 | Anti-CD19 (Human) mAb-FITC | 2019/03/31 | BC |
A07769 | Anti-CD19 (Human) mAb-PE | 2019/03/31 | BC |
A07770 | Anti-CD19 (Human) mAb-ECD | 2019/03/31 | BC |
A07771 | Anti-CD19 (Human) mAb-PC5 | 2019/03/31 | BC |
A07772 | Anti-CD20 (Human) mAb-FITC | 2019/03/31 | BC |
A07773 | Anti-CD20 (Human) mAb-PC5 | 2019/03/31 | BC |
A07774 | Anti-CD25 (Human) mAb-PE | 2019/03/31 | BC |
A07775 | Anti-CD33 (Human) mAb-PE | 2019/03/31 | BC |
A07776 | Anti-CD34 (Human) mAb-PE | 2019/03/31 | BC |
A07777 | Anti-CD34 (Human) mAb-PC5 | 2019/03/31 | BC |
A07778 | Anti-CD38 (Human) mAb-FITC | 2019/03/31 | BC |
A07779 | Anti-CD38 (Human) mAb-PE | 2019/03/31 | BC |
A07780 | Anti-CD38 (Human) mAb-PC5 | 2019/03/31 | BC |
A07781 | Anti-CD41 (Human) mAb-PE | 2019/03/31 | BC |
A07782 | Anti-CD45 (Human) mAb-FITC | 2019/03/31 | BC |
A07783 | Anti-CD45 (Human) mAb-PE | 2019/03/31 | BC |
A07784 | Anti-CD45 (Human) mAb-ECD | 2019/03/31 | BC |
A07785 | Anti-CD45 (Human) mAb-PC5 | 2019/03/31 | BC |
A07786 | Anti-CD45RA (Human) mAb-FITC | 2019/03/31 | BC |
A07787 | Anti-CD45RO (Human) mAb-PE | 2019/03/31 | BC |
A07788 | Anti-CD56 (Human) mAb-PE | 2019/03/31 | BC |
A07789 | Anti-CD56 (Human) mAb-PC5 | 2019/03/31 | BC |
A07790 | Anti-CD62P (P-Selectin) (Human) mAb-FITC | 2019/03/31 | BC |
A07791 | Anti-FMC7 (B Cells) (Human) mAb-FITC | 2019/03/31 | BC |
A07792 | Anti-CD235a (Glycophorin A) (Human) mAb-PE | 2019/03/31 | BC |
A07793 | Anti-HLA-DR (Human) mAb-PC5 | 2019/03/31 | BC |
A07794 | Mouse IgG1-FITC/Mouse IgG1-PE | 2019/03/31 | BC |
A07795 | Mouse IgG1 (isotype control)-FITC | 2019/03/31 | BC |
A07796 | Mouse IgG1 (isotype control)-PE | 2019/03/31 | BC |
A07797 | Mouse IgG1 (isotype control)-ECD | 2019/03/31 | BC |
A07798 | Mouse IgG1 (isotype control)-PC5 | 2019/03/31 | BC |
A08932 | Anti-CD5 (Human) mAb-FITC | 2019/03/31 | BC |
A08933 | Anti-CD109 (Human) mAb-PE | 2019/03/31 | BC |
A08934 | Anti-CD314 (NKG2D) (Human) mAb-PE | 2019/03/31 | BC |
A09142 | Mouse IgG2a (isotype control)-PE | 2019/03/31 | BC |
A09144 | Mouse IgG2a (isotype control)-ECD | 2019/03/31 | BC |
A09148 | Mouse IgG2a (isotype control)-PC5 | 2019/03/31 | BC |
A09778 | Anti-CD158a, h (Human) mAb-PE | 2019/03/31 | BC |
A10974 | Mouse IgG1-FITC/Mouse IgG2a-PE mAb | 2019/03/31 | BC |
A12689 | Mouse IgG2a (isotype control) mAb-FITC | 2019/03/31 | BC |
A12692 | Mouse IgG2a (isotype control) mAb-PC7 | 2019/03/31 | BC |
A12693 | Mouse IgG2a (isotype control) mAb-APC | 2019/03/31 | BC |
A17599 | Mouse IgG1-FITC/Mouse IgG2a-PE mAb | 2019/03/31 | BC |
A21689 | Anti-CD2 (Human) mAb-PC7 | 2019/03/31 | BC |
A21690 | Anti-CD5 (Human) mAb-PC7 | 2019/03/31 | BC |
A21691 | Anti-CD34 (Human) mAb-PC7 | 2019/03/31 | BC |
A21692 | Anti-CD56 (Human) mAb-PC7 | 2019/03/31 | BC |
A21693 | Anti-CD20 (Human) mAb-APC | 2019/03/31 | BC |
A22327 | Anti-Cyclin A2 (Human) mAb-FITC | 2019/03/31 | BC |
A22328 | Anti-CD300a (IRp60) (Human) mAb-PE | 2019/03/31 | BC |
A22329 | Anti-CD314 (NKG2D) (Human) mAb-APC | 2019/03/31 | BC |